NCT02857920View on ClinicalTrials.gov

Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 1, 2016

Primary Completion Date

August 1, 2017

Study Completion Date

August 1, 2019

Conditions
Malignant Solid Tumour
Interventions
DRUG

Bevacizumab

7.5 mg/kg, i.v, once every 3 weeks (continuous)

BIOLOGICAL

NK immunotherapy

Each treatment: 8\~10 billion cells in all, transfusion in 3 times, i.v.

Trial Locations (1)

510665

Fuda cancer institute of Fuda cancer hospital, Guangzhou

All Listed Sponsors
collaborator

Shenzhen Hank Bioengineering Institute

OTHER

lead

Fuda Cancer Hospital, Guangzhou

OTHER

NCT02857920 - Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter